Profile data is unavailable for this security.
About the company
SMS Pharmaceuticals Limited is an India-based pharmaceutical manufacturing company. The Company is engaged in the business of manufacturing of active pharma ingredients and their intermediates. Its product categories include anti-ulcer, anti-inflammatory, anti-migraine, ant-diabetic, anti-coagulant, anti-viral, anti-retroviral, anti-psychotic and others. The Company products include ranitidine, famotidine, pantoprazole sodium, itraconazole, lanoconazole, luliconazole, ibuprofen, Dex ibuprofen, fenoprofen calcium, sumatriptan, almotriptan, zolmitriptan, rizatriptan, Ele triptan, vildagliptin, sitagliptin, rosiglitazone, empagliflozin, dapagliflozin, tenofovir, dolutegravir, raltegravir, lamivudine, efavirenz, apixaban, rivaroxaban, levetiracetam, perampanel and lamotrigine. The Company has manufacturing facilities at Bachupally, Hyderabad, Telangana and also at Kandivalasa Village, Poosapatirega Mandal, Vijayanagaram District, Andhra Pradesh.
- Revenue in INR (TTM)6.13bn
- Net income in INR360.58m
- Incorporated1987
- Employees1.10k
- LocationSMS Pharmaceuticals LtdPlot No.19-III,OP BHARATIYA VIDYA BHAVANPUBLIC ROAD NO 71, JUBILEE HILLSHYDERABAD 500034IndiaIND
- Phone+91 4 066288888
- Fax+91 4 023551401
- Websitehttps://smspharma.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Remus Pharmaceuticals Ltd | 450.27m | 85.03m | 10.74bn | 38.00 | 114.05 | 41.33 | 119.57 | 23.85 | 63.92 | 63.92 | 361.02 | 176.36 | -- | -- | -- | 11,849,290.00 | -- | -- | -- | -- | 52.39 | -- | 18.88 | -- | 1.35 | -- | 0.2933 | -- | 82.17 | -- | 151.14 | -- | -- | -- |
| Vimta Labs Ltd | 3.20bn | 413.41m | 10.77bn | 1.37k | 26.45 | -- | 14.27 | 3.36 | 18.37 | 18.37 | 142.48 | -- | -- | -- | -- | 2,342,054.00 | -- | 10.50 | -- | 12.94 | 75.80 | 72.82 | 12.90 | 11.92 | -- | 28.50 | -- | 12.37 | 14.34 | 11.64 | 16.55 | 24.00 | 15.39 | 0.00 |
| Lincoln Pharmaceuticals Ltd | 5.51bn | 872.70m | 11.39bn | 1.70k | 13.05 | -- | 11.67 | 2.07 | 43.57 | 43.57 | 274.88 | -- | -- | -- | -- | 3,238,331.00 | -- | 13.75 | -- | 16.82 | 54.00 | 50.74 | 15.85 | 14.11 | -- | 41.54 | -- | 3.94 | 8.09 | 7.13 | 5.11 | 16.06 | 7.60 | 0.00 |
| Bliss GVS Pharma Ltd | 7.70bn | 754.54m | 11.51bn | 763.00 | 15.53 | 1.19 | 10.66 | 1.49 | 7.08 | 7.08 | 72.86 | 92.39 | 0.6498 | 3.45 | 1.95 | -- | 6.88 | 6.46 | 8.37 | 8.22 | 50.39 | 44.21 | 10.59 | 9.92 | 4.34 | 17.97 | 0.0905 | 7.93 | 2.48 | -3.03 | 6.49 | -9.42 | -8.33 | -12.94 |
| Kopran Ltd | 5.79bn | 403.74m | 11.52bn | 394.00 | 28.72 | -- | 21.77 | 1.99 | 8.32 | 8.32 | 119.70 | -- | -- | -- | -- | 14,693,070.00 | -- | 8.64 | -- | 12.88 | 35.60 | 34.36 | 6.97 | 8.71 | -- | 36.80 | -- | -- | 15.38 | 11.85 | -55.38 | 5.86 | 39.08 | -- |
| Syncom Formulations (India) Ltd | 2.50bn | 263.83m | 12.27bn | 799.00 | 38.38 | -- | 39.60 | 4.91 | 0.34 | 0.34 | 3.26 | -- | -- | -- | -- | 3,126,329.00 | -- | 7.69 | -- | 10.30 | 39.33 | 31.92 | 10.56 | 8.73 | -- | 4.72 | -- | -- | 2.09 | 7.17 | 1.42 | 18.34 | 25.48 | -- |
| Beta Drugs Ltd | 2.56bn | 347.57m | 12.66bn | 315.00 | 36.42 | 8.92 | 27.65 | 4.94 | 36.15 | 36.15 | 266.28 | 147.68 | 1.24 | 4.44 | 3.72 | 8,126,721.00 | 16.85 | -- | 25.36 | -- | 41.88 | -- | 13.58 | -- | 1.43 | 18.21 | 0.098 | -- | 23.54 | -- | 23.73 | -- | -- | -- |
| Zota Health Care Ltd | 1.68bn | -100.65m | 12.71bn | 338.00 | -- | -- | 179.08 | 7.58 | -3.95 | -3.95 | 65.73 | -- | -- | -- | -- | 4,961,589.00 | -- | 2.13 | -- | 2.78 | 43.59 | 32.39 | -6.00 | 2.01 | -- | -1.81 | -- | 115.52 | 6.68 | 12.45 | -164.81 | -- | 56.84 | -14.14 |
| Ngl Fine Chem Ltd | 3.17bn | 380.04m | 14.42bn | 343.00 | 37.95 | -- | 29.01 | 4.55 | 61.52 | 61.52 | 513.13 | -- | -- | -- | -- | 9,241,813.00 | -- | 15.74 | -- | 20.73 | 53.94 | 45.27 | 11.99 | 13.43 | -- | 34.92 | -- | 3.47 | -12.42 | 19.17 | -58.92 | 10.23 | 5.65 | -- |
| Hester Biosciences Ltd | 3.05bn | 188.89m | 14.67bn | 693.00 | 69.29 | 5.03 | 38.26 | 4.82 | 24.89 | 24.89 | 392.38 | 343.01 | 0.4572 | 1.20 | 3.85 | -- | 3.18 | 6.15 | 4.00 | 7.69 | 68.52 | 68.83 | 6.95 | 12.83 | 1.31 | 1.84 | 0.4466 | 23.27 | 14.45 | 11.33 | -29.06 | -14.59 | 1.49 | -11.42 |
| SMS Pharmaceuticals Ltd | 6.13bn | 360.58m | 16.97bn | 1.10k | 47.02 | -- | 23.45 | 2.77 | 4.26 | 4.26 | 72.40 | -- | -- | -- | -- | 5,597,176.00 | -- | 5.86 | -- | 7.77 | 31.67 | 33.18 | 6.65 | 8.34 | -- | 3.13 | -- | 6.26 | 0.4188 | 2.35 | -111.35 | -- | 28.46 | 3.71 |
| Solara Active Pharma Sciences Ltd | 14.07bn | -3.08bn | 18.79bn | 2.36k | -- | -- | -- | 1.34 | -85.65 | -85.65 | 390.73 | -- | -- | -- | -- | 5,958,916.00 | -- | 2.68 | -- | 4.10 | 40.47 | 44.49 | -21.88 | 4.58 | -- | -1.67 | -- | 10.10 | 13.83 | 22.61 | 61.86 | -- | 26.23 | -- |
| Themis Medicare Ltd | 3.64bn | 452.86m | 18.89bn | 996.00 | 41.77 | -- | 32.98 | 5.19 | 4.91 | 4.91 | 39.49 | -- | -- | -- | -- | 3,655,101.00 | -- | 9.59 | -- | 14.94 | 65.58 | 60.13 | 12.44 | 13.15 | -- | -- | -- | 7.33 | -10.21 | 10.85 | -21.93 | 38.18 | 24.51 | -- |
| Amrutanjan Health Care Ltd | 3.94bn | 440.09m | 21.24bn | 575.00 | 48.60 | -- | 42.62 | 5.38 | 15.13 | 15.13 | 135.41 | -- | -- | -- | -- | 6,860,612.00 | -- | 17.04 | -- | 21.22 | 49.51 | 54.08 | 11.16 | 13.37 | -- | 341.76 | -- | 17.21 | -6.46 | 11.37 | -40.71 | 14.72 | 23.87 | 10.64 |
| Suven Life Sciences Ltd | 116.93m | -1.05bn | 21.91bn | 132.00 | -- | 8.11 | -- | 187.34 | -4.82 | -4.82 | 0.5359 | 12.38 | 0.0347 | -- | 11.17 | -- | -31.19 | -46.46 | -32.37 | -50.52 | -- | -- | -898.63 | -787.61 | 18.94 | -849.16 | 0.0026 | -- | -13.64 | -47.23 | 11.15 | -- | -- | -- |
Data as of May 18 2024. Currency figures normalised to SMS Pharmaceuticals Ltd's reporting currency: Indian Rupee INR
1.98%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| quant Money Managers Ltd.as of 30 Apr 2024 | 1.68m | 1.98% |
| American Century Investment Management, Inc.as of 09 May 2024 | 881.00 | 0.00% |
| Motilal Oswal Asset Management Co. Ltd.as of 30 Apr 2024 | 342.00 | 0.00% |
Data from 31 Mar 2024 - 30 Apr 2024Source: FactSet Research Systems Inc.
